New pillars of optimal medical treatment in heart failure - report from ESC2024

Prof. Michael Böhm explains how SGLT-2 inhibitors became a strong pillar of treatment in HFrEF and HFpEF patients. Their antidiabetic effect and kidney protection make them a widely used tool in cardiovascular diseases. We learn where GLP-1 agonists stand in cardiovascular risk protection and how beneficial they are in overweight HFpEF patients. The new mineralocorticoid receptor antagonists (MRAs) also proved their role in HF treatment. The new, non-steroid MRA, finerenone improved CV outcomes in the FINEARTS-HF trial in HFpEF patients, presented at ESC2024. The MOONRAKER program will further investigate finerenone’s place in HF therapy. He stresses that we must use all 4 pillars of HF treatment. Video: https://medicaldigest.org/scientific-contents/interview:new-pillars-optimal-medical-treatment-heart-failure